Genetically modified mouse models for biomarker discovery and preclinical drug testing

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 625-630

  Kucherlapat, Raju ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BIOLOGICAL MARKER; CATHEPSIN B; CATHEPSIN D; PERIFOSINE; RAPAMYCIN;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER MODEL; CANCER RESEARCH; CELL GROWTH; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DNA MODIFICATION; DRUG EFFICACY; DRUG SCREENING; EMBRYONIC STEM CELL; EXPERIMENTAL MOUSE; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HOMOLOGOUS RECOMBINATION; IMAGE ANALYSIS; IN VITRO STUDY; NONHUMAN; ONCOGENE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856541266     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2021     Document Type: Conference Paper

References (20)

1. Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clin Cancer Res 2012;18:612-8.
2. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res 2012;18:638-44.
3. Blasberg R, Piwnica-Worms D. Imaging: strategies, controversies, and opportunities. Clin Cancer Res 2012;18:631-7.
4. Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 2012;18:619-24.
5. Anderson KC, DuBois RN. Overview of the AACR Clinical and Translational Cancer Research Think Tank meeting. Clin Cancer Res 2012;18:607-11.
6. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981;292:154-6. (Pubitemid 11050741)
7. Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, Thompson S, et al. Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 1987;330:576-8. (Pubitemid 17164356)
8. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987;51:503-12.
9. Hung KE, Kho AT, Sarracino D, Richard LG, Krastins B, Forrester S, et al. Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J Proteome Res 2006;5:1866-78.
10. Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, et al. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) 2009;2:224-33.
11. Chan AT, Baba Y, Shima K, Nosho K, Chung DC, Hung KE, et al. Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. Cancer Epidemiol Biomarkers Prev 2010;19:2777-85.
12. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5: e123.
13. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20:289-99.
14. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006;20:1496-510. (Pubitemid 43830656)
15. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62. (Pubitemid 34008191)
16. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM, Schrump DS. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog 1996; 17:217-23. (Pubitemid 27050722)
17. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 2010;107:1565-70.
18. Wu R, Hu T, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011;17: 7359-72.
19. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-33. (Pubitemid 46518315)
20. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104-7.